BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Odri GA, Tchicaya-Bouanga J, Yoon DJY, Modrowski D. Metastatic Progression of Osteosarcomas: A Review of Current Knowledge of Environmental versus Oncogenic Drivers. Cancers (Basel) 2022;14:360. [PMID: 35053522 DOI: 10.3390/cancers14020360] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Hua L, Lei P, Hu Y. Construction and validation model of necroptosis-related gene signature associates with immunity for osteosarcoma patients. Sci Rep 2022;12:15893. [PMID: 36151259 DOI: 10.1038/s41598-022-20217-4] [Reference Citation Analysis]
2 Alsaeed MA, Ebrahimi S, Alalikhan A, Hashemi SF, Hashemy SI, De Vita A. The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis. BioMed Research International 2022;2022:1-9. [DOI: 10.1155/2022/8082608] [Reference Citation Analysis]
3 Jambi EJ, Abdulaziz Alshubaily F. Shilajit potentiates the effect of chemotherapeutic drugs and mitigates metastasis induced liver and kidney damages in osteosarcoma rats. Saudi Journal of Biological Sciences 2022;29:103393. [DOI: 10.1016/j.sjbs.2022.103393] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Huang J, Zhang J, Xiao H. Identification of Epigenetic-Dysregulated lncRNAs Signature in Osteosarcoma by Multi-Omics Data Analysis. Front Med 2022;9:892593. [DOI: 10.3389/fmed.2022.892593] [Reference Citation Analysis]